Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 12/20 | 0.68 |
| ▸ | EBP | Q15125 | 5/20 | 0.62 |
| ▸ | DHCR7 | Q9UBM7 | 5/20 | 0.62 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.56 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22033858 | 0.94 | EPHX2 (0.62) | EPHX2EBPDHCR7NPSR1 | |
| SCHEMBL22032754 | 0.89 | EPHX2 (0.70) | EPHX2EBPDHCR7NPSR1 | |
| SCHEMBL22033224 | 0.84 | EPHX2 (0.62) | EPHX2EBPDHCR7NPSR1NPC1 | |
| SCHEMBL22032778 | 0.81 | EBP (0.69) | EPHX2EBPDHCR7NPSR1 | |
| SCHEMBL10019213 | 0.80 | EPHX2 (1.00) | EPHX2 | |
| SCHEMBL10019214 | 0.80 | EPHX2 (1.00) | EPHX2 | |
| SCHEMBL22032812 | 0.79 | EBP (0.59) | EPHX2EBPDHCR7NPSR1 | |
| SCHEMBL17007461 | 0.78 | EBP (0.97) | EPHX2EBPDHCR7NPSR1NPC1 | |
| SCHEMBL9621707 | 0.77 | EBP (0.71) | EPHX2EBPDHCR7NPSR1NPC1 | |
| SCHEMBL17007504 | 0.77 | EBP (1.00) | EPHX2EBPDHCR7NPSR1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220024891-A1 | THERAPEUTICS TARGETING MUTANT ADENOMATOUS POLYPOSIS COLI (APC) FOR THE TREATMENT OF CANCER | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2022-01-27 | — | — | US | disclosed |
| EP-3890715-A1 | THERAPEUTICS TARGETING MUTANT ADENOMATOUS POLYPOSIS COLI (APC) FOR THE TREATMENT OF CANCER | The Board Of Regents Of The University Of Texas System (US) | 2021-10-13 | — | — | EP | disclosed |
| WO-2020117972-A1 | THERAPEUTICS TARGETING MUTANT ADENOMATOUS POLYPOSIS COLI (APC) FOR THE TREATMENT OF CANCER | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2020-06-11 | — | — | WO | disclosed |
| WO-2020117972-A1 | THERAPEUTICS TARGETING MUTANT ADENOMATOUS POLYPOSIS COLI (APC) FOR THE TREATMENT OF CANCER | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2020-06-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220024891-A1 | THERAPEUTICS TARGETING MUTANT ADENOMATOUS POLYPOSIS COLI (APC) FOR THE TREATMENT OF CANCER | APC, VHL, KRAS | EPHX2 3846/4885EBP 4598/4885DHCR7 3774/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.